Stock Alert: Second Sight Medical Products Surges 65%

Shares of Second Sight Medical Products, Inc. (EYES) are surging about 65% on Monday morning. Last Friday the company said FDA approved its Argus 2s Retinal Prosthesis System for the treatment of retinitis pigmentosa.

EYES is currently trading at $9.47, up $3.68 or 63.56%, on the Nasdaq.

Retinitis pigmentosa is a genetic disorder that affects cells in the retina leading to loss of sight. Argus 2s is a set of external hardware, glasses and video processing unit, to be used in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa.

Second Sight Medical Products develops implantable visual prosthetics that are intended to deliver artificial vision to blind individuals.

Source: Read Full Article